Current Report Filing (8-k)
December 03 2018 - 5:07PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
|
Date of report (Date of earliest event reported):
November 27,
2018
|
Enzo Biochem, Inc.
(Exact Name of Registrant as Specified
in Its Charter)
New York
(State or Other Jurisdiction of Incorporation)
001-09974
|
13-2866202
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
|
527 Madison Avenue
|
|
New York, New
York
|
10022
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
(212) 583-0100
(Registrant’s Telephone Number, Including
Area Code)
(Former Name or Former Address, if Changed
Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (
see
General Instruction
A.2. below):
o
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
|
|
o
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
|
o
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange
Act (17 CFR 240.14d-2(b))
|
|
|
o
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 450 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-1 of this chapter).
Emerging growth company
o
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
o
Item 2.03 Creation
of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
On November 27, 2018, Enzo Biochem, Inc. (the “Company”)
closed on the $6 million purchase of a new facility adjacent to its current campus in Farmingdale, NY to be used for manufacturing
and distributing its low cost, diagnostic platform products and related services.
In connection with the acquisition of the facility, the Company
entered into a fee mortgage security agreement with Citibank, N.A., the mortgagee in the amount of $4.5 million. The mortgage
is for a term of 10 years, bears a fixed interest rate of 5.09% per annum, and requires monthly debt service and interest payments
of $30,105.84. The mortgage includes financial covenants requiring adherence to certain financial ratios. The Company has Town
of Babylon Industrial Development Agency (IDA) commitments that will provide significant multi-year tax abatements and additional
incentives with respect to its entire Farmingdale campus
The Company is assuming a short term occupancy lease with an
existing tenant from the seller. The tenant may occupy the facility until December 2019, unless it is given or gives notice to
vacate prior to that date.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
ENZO BIOCHEM, INC.
|
|
|
|
|
|
Date: December 3, 2018
|
By:
|
/s/ Barry W. Weiner
|
|
|
|
Barry W. Weiner
|
|
|
|
President
|
|
|
|
|
|
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Mar 2024 to Apr 2024
Enzo Biochem (NYSE:ENZ)
Historical Stock Chart
From Apr 2023 to Apr 2024